Replimune Group Stock

Replimune Group EBITDA per Share

The EBITDA per Share of Replimune Group (REPL) as of Aug 5, 2026 is -3.45 USD. In the previous year, EBITDA per Share was -2.81 USD — a change of 22.61% (lower).

EBITDA per Share

-3.45USD

YoY

22.61%

Last updated:

EBITDA per Share of Replimune Group is 2026 -3.45 USD. EBITDA per Share of Replimune Group was 2025 -2.81 USD. It decreases by 22.61% lower compared to the previous year.
Access this data via the Eulerpool API

Replimune Group Stock analysis

What does Replimune Group do? Replimune Group Inc is an American biotechnology company based in Woburn, Massachusetts. The company focuses on the development of therapeutics for cancer treatments through the application of oncolytic viruses. Replimune Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Replimune Group stock

EBITDA per Share of Replimune Group is -3.45 USD in 2026.

EBITDA per Share of Replimune Group changed from -2.81 USD to -3.45 USD, representing a 22.61% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Replimune Group since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

Income Statement — Replimune Group

All Key Metrics — Replimune Group